The Company develops, acquires and commercializes novel treatments for cancer and focuses its research and in-licensing activities on identifying and developing new, less toxic and effective ways to treat cancer.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Will gain substantially when Pix is submitted for approval, sometime within the next month or so. Then the next big jump will come upon approval by the FDA, if given priority review, by the end of the year. Great buy now, hold for 5 months, then strong buy again. very sttrong pipeline for future company growth and eliminating debt faster than expected.